Kitov Pharmaceuticals Holdings (KTOV) Receiving Somewhat Favorable Press Coverage, Report Finds
News headlines about Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kitov Pharmaceuticals Holdings earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.1420466758638 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment’s rankings:
- Kitov Pharma (KTOV) Reports FDA Filing for New Drug Application for KIT-302 (streetinsider.com)
- Kitov files U.S. marketing application for lead candidate KIT-302; shares ahead 8% premarket (seekingalpha.com)
- Kitov Announces Filing by FDA of New Drug Application for KIT-302 (finance.yahoo.com)
- Composite Session Friday Leading Losers, Summary (fxpips.com)
- Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) Stock Closed Much Higher Than Its 50 Day Average – First News 24 (firstnewspaper24.com)
Shares of Kitov Pharmaceuticals Holdings (NASDAQ:KTOV) traded down 10.5307% during mid-day trading on Monday, hitting $1.9133. 914,025 shares of the stock traded hands. The company’s market cap is $14.66 million. Kitov Pharmaceuticals Holdings has a one year low of $1.27 and a one year high of $4.55. The stock has a 50 day moving average price of $1.87 and a 200-day moving average price of $1.86.
TRADEMARK VIOLATION NOTICE: “Kitov Pharmaceuticals Holdings (KTOV) Receiving Somewhat Favorable Press Coverage, Report Finds” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/02/kitov-pharmaceuticals-holdings-ktov-receiving-somewhat-favorable-press-coverage-report-finds.html.
Kitov Pharmaceuticals Holdings Company Profile
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
Receive News & Stock Ratings for Kitov Pharmaceuticals Holdings Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals Holdings Ltd. and related stocks with our FREE daily email newsletter.